Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy

Basic Information

Funding Cycle : 2023-2024
Name : Kylee Maclachlan
Type of Award : Translational Research Award
Home Institution : Memorial Sloan Kettering Cancer Center


This study aims to comprehensively characterize the genomic and immune landscape of newly diagnosed multiple myeloma (NDMM) patients treated with daratumumab-based quadruplet induction therapy (dara-quads). Preliminary data suggests that standard prognostic scores are inadequate for predicting outcomes, necessitating the inclusion of complex genomic and immune features. Specific Aim 1 focuses on identifying genomic features associated with response to dara-quads, including APOBEC mutational activity and intra-clonal heterogeneity. Specific Aim 2 aims to examine how immune composition may predict early relapse, in conjunction with genomic risk factors. The study utilizes both bulk and single-cell whole genome sequencing, along with immune assessment by CITE-seq, to provide a comprehensive understanding of NDMM treatment response and relapse prediction.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events